Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416618 | 0.74 | MAPK1 (0.42) | MAPKAPK2RPS6KA3CSNK2A1PLK3 | |
| SCHEMBL5828182 | 0.73 | MAPT (0.44) | ALDH1A1 | |
| SCHEMBL1257032 | 0.69 | MAPKAPK2 (0.51) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL31156527 | 0.69 | MAPKAPK2 (0.51) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL6770705 | 0.69 | — | — | |
| SCHEMBL4427845 | 0.69 | MAPKAPK2 (0.44) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL4427818 | 0.68 | CMA1 (0.38) | ALDH1A1 | |
| SCHEMBL4422632 | 0.68 | KMO (0.44) | ALDH1A1 | |
| SCHEMBL706525 | 0.67 | MAPKAPK2 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL31214307 | 0.67 | RPS6KA3 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | claimed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | claimed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | claimed |
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | disclosed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | MAPKAPK2 3886/4885RPS6KA3 2374/4885CSNK2A1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.